Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

642.25 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
5 Revealing Analyst Questions From Regeneron’s Q3 Earnings Call
Regeneron’s third quarter results were well received by the market, reflecting strong execution in its commercial portfolio and key products. Management attributed the positive momentum to double-digit... 
Via StockStory
Topics Earnings
Michael Burry Is Super-Bearish On Palantir — With 5 Million Puts
Michael Burry's Scion Asset Management filed an updated 13F showing a new large bearish position in Palantir and Nvidia, among others. 
Via Benzinga
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings Scheduled For October 28, 2025
 
Via Benzinga
2 Beaten-Down Stocks That Could Be About to Rally
It would be best to get in before the rest of the market pounces on these opportunities. 
Via The Motley Fool
Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
REGN Q3 Deep Dive: Pipeline, Regulatory Progress, and Label Expansion Take Center Stage
Biotech company Regeneron (NASDAQ:REGN) reported Q3 CY2025 results exceeding the market’s revenue expectations, but sales were flat year on year at $3.75 billion. Its non-GAAP profit of $11.83 per... 
Via StockStory
Regeneron (REGN) Q3 2025 Earnings Call Transcript
Regeneron (REGN) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Uncover the latest developments among S&P500 stocks in today's session.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Tuesday as we examine the latest happenings in today's session. 
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session.
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
Why Are Regeneron (REGN) Shares Soaring Today
Shares of biotech company Regeneron (NASDAQ:REGN) jumped 8.7% in the morning session after it reported third-quarter financial results that surpassed analyst expectations for both revenue and profit. 
Via StockStory
Topics Artificial Intelligence
Nasdaq 100 Hits 26,000, Gold Falls Below $4,000: What's Moving Markets Tuesday?
Tech stocks hit new highs as the Nasdaq 100 rallies 0.7% midday. Investors eye a Fed rate cut, Trump-Xi meeting, and major tech earnings. 
Via Benzinga
Topics Economy
These S&P500 stocks are gapping in today's session
Let's have a look at the S&P500 gap up and gap down stocks in today's session. 
Via Chartmill
Wayfair, Qorvo, Celestica, United Parcel Service, Regeneron Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
These S&P500 stocks that are showing activity before the opening bell on Tuesday.
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements. 
Via Chartmill
Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness
Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea sales. 
Via Benzinga
Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts
Regeneron stock advanced early Tuesday on better-than-expected third-quarter earnings despite a big tax hit. 
Via Investor's Business Daily
Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 2025 Earnings Beat Estimates
Regeneron (REGN) Q3 2025 earnings beat estimates with $11.83 EPS on $3.75B revenue. Strong performance driven by Dupixent and Libtayo sales growth. 
Via Chartmill
Topics Earnings
Regeneron (NASDAQ:REGN) Surprises With Strong Q3
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q3 CY2025, but sales were flat year on year at $3.75 billion. Its non-GAAP profit of $11.83 per share was... 
Via StockStory
Regeneron Reports Third Quarter 2025 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Market's Perilous Peak: Is the U.S. Stock Market More Overvalued Than Ever?
New York, NY – October 27, 2025 – A chorus of concern is growing louder across financial markets, with prominent voices like MarketWatch raising alarm bells over what they describe as an unprecedented... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
A Preview Of Regeneron Pharmaceuticals's Earnings
 
Via Benzinga
Regeneron Earnings: What To Look For From REGN
Biotech company Regeneron (NASDAQ:REGN) will be announcing earnings results this Tuesday before market open. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
Sanofi Soars as Dupixent Sales Near €5 Billion Amidst Intensifying Trump Drug Pricing Negotiations
Paris, France – October 24, 2025 – Pharmaceutical giant Sanofi (EURONEXT: SAN, NASDAQ: SNY) saw its shares climb today following the announcement of stellar third-quarter 2025 financial results,... 
Via MarketMinute
Topics Government World Trade
Immuno-Oncology Stocks Q2 Recap: Benchmarking Exact Sciences (NASDAQ:EXAS)
Looking back on immuno-oncology stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Exact Sciences (NASDAQ:EXAS) and its peers. 
Via StockStory
Topics Artificial Intelligence
Reflecting On Immuno-Oncology Stocks’ Q2 Earnings: Natera (NASDAQ:NTRA)
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the immuno-oncology industry, including Natera (NASDAQ:NTRA) and its peers. 
Via StockStory
Topics Artificial Intelligence
Here's How Much $1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today
 
Via Benzinga
The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly.
The Commissioner's National Priority Review vouchers aims to speed up the review process to just one to two months. 
Via Investor's Business Daily
FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times
The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, and other conditions. 
Via Benzinga
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
Positive opinion based on results of Phase 3 C-POST trial that show Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence... 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.